About this podcast
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episodes
The newest 50 of 408 episodes
- Ep. 398 - J&J’s $2B NewCo Buy, Neoantigen Vaccines, Overton Odds · 29 min · Season 7 Episode 398J&J will pay $2.2 billion upfront to acquire Ollin, a Texas-based NewCo with China-sourced assets, gaining a late-stage VEGF x Ang2 bispecific for wet AMD and diabetic macular…
- Ep. 397 - What the U.S. midterms mean for biopharma · 28 min · Season 7 Episode 397Midterm election results in the U.S. have short-circuited plans to install a Senate-confirmed FDA commissioner and could open a narrow path to bipartisan drug pricing…
- Ep. 396 - China’s first-order innovation · 30 min · Season 7 Episode 396Rising first-in-class innovation, faster IND reviews and deep patient pools are drawing global biotechs to China, even as U.S. outbound investment restrictions loom. In a special…
- Ep. 395 - ESMO analysis & Auchincloss proposal · 33 min · Season 7 Episode 395A BioCentury analysis of ESMO first-in-human abstracts finds antibody-drug conjugates outnumbering every other modality, even as payload innovation lags behind target innovation…
- Ep. 394 - Security concerns in U.S., China reshaping biotech · 34 min · Season 7 Episode 394Proposed U.S. Treasury rules implementing the COINS Act would bar U.S. equity investments, joint ventures and co-development deals with China biotechs, potentially ensnaring…
- Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau · 30 min · Season 7 Episode 393Roche’s $15 billion biobucks deal with Hansoh for preclinical ADCs is the latest in a string of China licensing deals carrying unusually large upfronts for early-stage assets. On…
- Ep. 392 - Biotech markets: Pause before the storm? · 25 min · Season 7 Episode 392An M&A-fueled first half gave way to third-quarter underperformance for biotech as a short squeeze in Moderna forced specialist funds into selling some quality names and…
- Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners · 30 min · Season 7 Episode 391Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and…
- Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways · 34 min · Season 7 Episode 390Mechanisms broad enough to matter across many diseases, from mitochondrial health to the biology of aging, emerged as a defining theme at Grand Rounds Europe in Amsterdam. On a…
- Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look · 37 min · Season 7 Episode 389Seven global approvals in five years, validated biomarkers and FDA flexibility have turned IgA nephropathy from a neglected rare disease into a crowded field, with Biogen…
- Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs · 32 min · Season 7 Episode 388The first biotech IPO in a month, Electra's upsized $350 million offering, fell in its trading debut, testing investor appetite while a wave of reverse mergers showcases an…
- Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs · 31 min · Season 7 Episode 387Note: This episode was briefly published with an incorrect audio file, which has since been corrected. FDA is prepared to approve psychedelic therapies for chronic psychiatric…
- Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs · 35 min · Season 7 Episode 386A pair of high profile clinical setbacks has wiped out more than $40 billion in market cap for Novartis, most of which stemmed from the Phase III miss of antisense…
- Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton · 36 min · Season 7 Episode 385Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals with the White House. On the latest BioCentury This Week podcast…
- Ep. 384 - Back to School Special: The global FIH trials race · 43 minChina has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world…
- Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick · 19 min · Season 7 Episode 383A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized neoantigen vaccines. On the latest BioCentury This Week podcast…
- Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA · 25 min · Season 7 Episode 382A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss…
- Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs · 32 min · Season 7 Episode 381Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Australia, and beyond to run first in human trials faster and more…
- Ep. 380 - AZ-BMS rumors, Replimune, psychedelics · 32 min · Season 7 Episode 380Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s…
- Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard · 34 min · Season 7 Episode 379Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product upon which it can run the…
- Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data · 42 minThe departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what Vallance’s…
- Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson · 29 min · Season 7 Episode 377After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector’s traditional…
- Ep. 376 - M&A momentum: 3Q public markets preview · 33 min · Season 7 Episode 376M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets…
- Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech · 34 min · Season 7 Episode 375Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week…
- Ep. 374 - Parkinson's deep dive & FDA trial reforms · 34 min · Season 7 Episode 374New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury…
- Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first · 30 min · Season 7 Episode 373AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week…
- Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline · 25 min · Season 7 Episode 372Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for…
- Ep. 371 - Moving faster at the academia-industry interface · 33 min · Season 7 Episode 371Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too. From AI to NAMs to starting a Phase I…
- Ep. 370 - Calmer waters for FDA; Servier, Lilly deals · 35 min · Season 7 Episode 370FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week…
- Ep. 369 - ASCO advances, China innovation & U.S. science under threat · 39 min · Season 7 Episode 369Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast…
- Ep. 368 - ASCO Preview, China Policy, ADC Linkers · 34 min · Season 7 Episode 368At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics…
- Ep. 367 - FDA, obesity targets and the rise of DACs · 31 min · Season 7 Episode 367Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast…
- Ep. 366 - Europe's need for speed: Bio€quity takeaways · 44 min · Season 7 Episode 366China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special…
- Ep. 365 - Thin ice for Makary, redosing AAVs · 31 min · Season 7 Episode 365Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from…
- Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies · 32 min · Season 7 Episode 364UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T…
- Ep. 363 - New targets at AACR, biopharma deals, Kurma fund · 30 min · Season 7 Episode 653More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune…
- Ep. 362 - AACR: Data and de-risking · 25 min · Season 7 Episode 362Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs…
- Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers · 44 min · Season 7 Episode 361The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon…
- Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds · 34 min · Season 7 Episode 360A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On…
- Ep. 359 - 2Q markets preview, tariffs and biotech takeouts · 39 min · Season 7 Episode 359Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt…
- Ep. 358 - Europe's biotech challenge · 24 min · Season 7 Episode 358Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum…
- Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision · 29 min · Season 7 Episode 357A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos…
- Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN · 34 min · Season 7 Episode 356After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s…
- Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline · 25 min · Season 7 Episode 355Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will…
- Ep. 354 - East-West Summit Takeaways · 26 min · Season 7 Episode 354Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterparts. On a special edition of…
- Ep. 353 - Prasad Departure and Future of Fibrosis Therapies · 37 min · Season 7 Episode 353The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor tasked with keeping FDA out of…
- Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight · 35 min · Season 7 Episode 352Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this…
- Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint · 35 min · Season 7 Episode 351Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest…
- Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA · 26 min · Season 7 Episode 350As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This…
- Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch · 34 min · Season 7 Episode 3492025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion from the prior two years. On the…








